Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis

Aaron Wolfson, Isildinha Reis, Lorraine Portelance, Dayssy A. Diaz, Wei Zhao, Randall K. Gibb

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: This study accessed the Surveillance, Epidemiology and End Results (SEER) database to determine if tumor size is an independent predictor of overall survival (OS) for patients with stages I and II vaginal cancer (VC). Materials and methods: We identified in the SEER database, patients with available tumor size having stage I or II squamous cell histology from January 2004 through December 2012 with minimum follow-up of six months. Univariate analyses (UA) and multivariable analyses (MVA) evaluated the effect of several prognostic factors, including tumor size, regarding OS. Results: 529 SEER patients were found with recorded tumor sizes, of which 293 (55.4%) were stage I and 236 (44.6%) stage II. UA found the following significant prognostic factors of worse OS: tumor size >. 2. cm (HR = 1.80, p = 0.02) and older age at diagnosis (p. . 2. cm (HR = 2.13, p = 0.04) and older age at diagnosis (p. . 2. cm were 79.2% vs. 66.1% in stage I (p = 0.0187) and 80.9% vs. 51.2% in stage II (p = 0.0369). MVA confirmed about double risk of death for patients with tumor size >. 2. cm (HRs: 1.88 in stage I and 2.06 in stage II). Conclusions: Tumor size seems to predict OS outcome in patients with stages I/II VC. Further confirmatory investigations are recommended to firmly establish its incorporation into currently accepted staging criteria for these patients.

Original languageEnglish (US)
JournalGynecologic Oncology
DOIs
StateAccepted/In press - Dec 8 2015

Fingerprint

Vaginal Neoplasms
Epidemiology
Survival
Neoplasms
Databases
Histology
Epithelial Cells

Keywords

  • Prognostic factors
  • SEER analyses
  • Staging criteria
  • Tumor size
  • Vaginal cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

@article{a5437d6c906442a9981424e4b7a3d793,
title = "Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis",
abstract = "Purpose: This study accessed the Surveillance, Epidemiology and End Results (SEER) database to determine if tumor size is an independent predictor of overall survival (OS) for patients with stages I and II vaginal cancer (VC). Materials and methods: We identified in the SEER database, patients with available tumor size having stage I or II squamous cell histology from January 2004 through December 2012 with minimum follow-up of six months. Univariate analyses (UA) and multivariable analyses (MVA) evaluated the effect of several prognostic factors, including tumor size, regarding OS. Results: 529 SEER patients were found with recorded tumor sizes, of which 293 (55.4{\%}) were stage I and 236 (44.6{\%}) stage II. UA found the following significant prognostic factors of worse OS: tumor size >. 2. cm (HR = 1.80, p = 0.02) and older age at diagnosis (p. . 2. cm (HR = 2.13, p = 0.04) and older age at diagnosis (p. . 2. cm were 79.2{\%} vs. 66.1{\%} in stage I (p = 0.0187) and 80.9{\%} vs. 51.2{\%} in stage II (p = 0.0369). MVA confirmed about double risk of death for patients with tumor size >. 2. cm (HRs: 1.88 in stage I and 2.06 in stage II). Conclusions: Tumor size seems to predict OS outcome in patients with stages I/II VC. Further confirmatory investigations are recommended to firmly establish its incorporation into currently accepted staging criteria for these patients.",
keywords = "Prognostic factors, SEER analyses, Staging criteria, Tumor size, Vaginal cancer",
author = "Aaron Wolfson and Isildinha Reis and Lorraine Portelance and Diaz, {Dayssy A.} and Wei Zhao and Gibb, {Randall K.}",
year = "2015",
month = "12",
day = "8",
doi = "10.1016/j.ygyno.2016.03.009",
language = "English (US)",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer

T2 - A SEER analysis

AU - Wolfson, Aaron

AU - Reis, Isildinha

AU - Portelance, Lorraine

AU - Diaz, Dayssy A.

AU - Zhao, Wei

AU - Gibb, Randall K.

PY - 2015/12/8

Y1 - 2015/12/8

N2 - Purpose: This study accessed the Surveillance, Epidemiology and End Results (SEER) database to determine if tumor size is an independent predictor of overall survival (OS) for patients with stages I and II vaginal cancer (VC). Materials and methods: We identified in the SEER database, patients with available tumor size having stage I or II squamous cell histology from January 2004 through December 2012 with minimum follow-up of six months. Univariate analyses (UA) and multivariable analyses (MVA) evaluated the effect of several prognostic factors, including tumor size, regarding OS. Results: 529 SEER patients were found with recorded tumor sizes, of which 293 (55.4%) were stage I and 236 (44.6%) stage II. UA found the following significant prognostic factors of worse OS: tumor size >. 2. cm (HR = 1.80, p = 0.02) and older age at diagnosis (p. . 2. cm (HR = 2.13, p = 0.04) and older age at diagnosis (p. . 2. cm were 79.2% vs. 66.1% in stage I (p = 0.0187) and 80.9% vs. 51.2% in stage II (p = 0.0369). MVA confirmed about double risk of death for patients with tumor size >. 2. cm (HRs: 1.88 in stage I and 2.06 in stage II). Conclusions: Tumor size seems to predict OS outcome in patients with stages I/II VC. Further confirmatory investigations are recommended to firmly establish its incorporation into currently accepted staging criteria for these patients.

AB - Purpose: This study accessed the Surveillance, Epidemiology and End Results (SEER) database to determine if tumor size is an independent predictor of overall survival (OS) for patients with stages I and II vaginal cancer (VC). Materials and methods: We identified in the SEER database, patients with available tumor size having stage I or II squamous cell histology from January 2004 through December 2012 with minimum follow-up of six months. Univariate analyses (UA) and multivariable analyses (MVA) evaluated the effect of several prognostic factors, including tumor size, regarding OS. Results: 529 SEER patients were found with recorded tumor sizes, of which 293 (55.4%) were stage I and 236 (44.6%) stage II. UA found the following significant prognostic factors of worse OS: tumor size >. 2. cm (HR = 1.80, p = 0.02) and older age at diagnosis (p. . 2. cm (HR = 2.13, p = 0.04) and older age at diagnosis (p. . 2. cm were 79.2% vs. 66.1% in stage I (p = 0.0187) and 80.9% vs. 51.2% in stage II (p = 0.0369). MVA confirmed about double risk of death for patients with tumor size >. 2. cm (HRs: 1.88 in stage I and 2.06 in stage II). Conclusions: Tumor size seems to predict OS outcome in patients with stages I/II VC. Further confirmatory investigations are recommended to firmly establish its incorporation into currently accepted staging criteria for these patients.

KW - Prognostic factors

KW - SEER analyses

KW - Staging criteria

KW - Tumor size

KW - Vaginal cancer

UR - http://www.scopus.com/inward/record.url?scp=84962195182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962195182&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.03.009

DO - 10.1016/j.ygyno.2016.03.009

M3 - Article

C2 - 26970567

AN - SCOPUS:84962195182

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -